Short answer
Zimmer Biomet (ZBH) filed its Q1 2025 10-Q quarterly report on May 5, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $1.9B (up 1.1% year over year) with net income of $182M.
Q1 2025 key financials · XBRL
- Revenue
- $1.9B
- +1.1% YoY
- Net income
- $182M
- +5.6% YoY
- Operating margin
- 15.3%
- EPS (diluted)
- $0.91
- +8.3% YoY
Source: XBRL data from the Zimmer Biomet (ZBH) Q1 2025 10-Q on SEC EDGAR. USD.
Zimmer Biomet Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or changed risk factors disclosed compared to 2024 Form 10-K
- Continued risks include product liability and recall exposure impacting operations and financial condition
- Regulatory risk from evolving FDA and international medical device requirements affecting product approvals
- Operational risk from supply chain disruptions and manufacturing challenges influencing near-term performance
- Financial risk related to currency fluctuations impacting revenue given global sales exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zimmer Biomet quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.